News
Trial results, approvals, pricing changes, safety findings and market moves across peptides and GLP-1 medications — each traced to a primary source, each dated. For enforcement actions specifically, see the regulatory tracker.
- Trial results
- Approvals
- Pricing changes
- Safety findings
-
FDA approves Mounjaro to lower cardiovascular risk in type 2 diabetes
Read more: FDA approves Mounjaro to lower cardiovascular risk in type 2 diabetesThe FDA has approved a new indication for Mounjaro (tirzepatide): lowering the risk of major adverse cardiovascular events — cardiovascular death, non-fatal heart attack, or non-fatal stroke — in adults with type 2 diabetes who are at high risk for them. Eli Lilly announced the approval on 28 August 2026. It is the first cardiovascular…
-
Large cohort links GLP-1 drugs to more diabetic retinopathy, not to vision loss
Read more: Large cohort links GLP-1 drugs to more diabetic retinopathy, not to vision lossA large propensity-matched cohort study published in Diabetes, Obesity and Metabolism on 27 August 2026 found that people who started a GLP-1 receptor agonist were modestly more likely to be diagnosed with diabetic retinopathy, and more likely to undergo a retinopathy procedure, than matched people who started a DPP-4 inhibitor instead. The same study found…
-
Only 3 in 100 people on semaglutide hit the combined target in a 45,000-patient real-world study
Read more: Only 3 in 100 people on semaglutide hit the combined target in a 45,000-patient real-world studyTrial results describe what happens under close supervision with motivated volunteers. A study published in August in The Lancet Diabetes & Endocrinology asked a harder question: among 45,093 real patients with obesity and type 2 diabetes, how many actually hit a meaningful combined target a year after starting treatment? The answer for semaglutide was 3.0%.…
-
Lilly-authored analysis says Zepbound offsets other healthcare costs after 55
Read more: Lilly-authored analysis says Zepbound offsets other healthcare costs after 55Eli Lilly announced on 26 August 2026 that a real-world analysis of adults over 55 found lower healthcare costs among people who stayed on Zepbound (tirzepatide) than among matched untreated adults, and framed the result against the $195 monthly net price under Medicare’s GLP-1 Bridge programme. The underlying paper is peer-reviewed and published in Diabetes,…
-
A higher semaglutide dose reached 20.7% weight loss. It closes some of the gap to tirzepatide
Read more: A higher semaglutide dose reached 20.7% weight loss. It closes some of the gap to tirzepatideThe standard maintenance dose of Wegovy is 2.4 mg a week. STEP UP, a phase 3b randomised trial published in The Lancet Diabetes & Endocrinology, tested three times that — 7.2 mg — against both the standard dose and placebo over 72 weeks. Average weight loss was 20.7% on the high dose, 17.5% on 2.4…
-
Tirzepatide beat semaglutide head to head. The trial has two caveats worth knowing
Read more: Tirzepatide beat semaglutide head to head. The trial has two caveats worth knowingThe question people ask most often about these two drugs — which one works better — has a direct answer, and has had one since July 2025. In SURMOUNT-5, a trial that gave 751 adults either tirzepatide or semaglutide and followed them for 72 weeks, tirzepatide produced an average weight reduction of 20.2% against semaglutide’s…
-
Novo is cutting list prices by half. Cash payers will not notice
Read more: Novo is cutting list prices by half. Cash payers will not noticeNovo Nordisk announced in February that from 1 January 2027 it will cut the US list price of Wegovy, Ozempic and Rybelsus to $675 a month — a reduction of roughly 50% for Wegovy and 35% for Ozempic. It is a genuinely large number and it made a lot of headlines. For most people reading…